1. Aide
    1. Espace Client
    2. Connexion
  1. Aide
    1. Espace Client
    2. Connexion
Espace Membre Boursorama

Erreur d'authentification

Vous êtes authentifié. Nous chargeons votre espace membre.

Mot de passe oublié ?

Nouveau sur Boursorama ? Devenez membre

Identifiant/Mot de passe oublié
Si vous êtes Membre de la Communauté Boursorama, veuillez indiquer l'adresse email que vous avez fournie lors de votre enregistrement pour recevoir votre identifiant et/ou ré-initialiser votre mot de passe :

Nouveau sur Boursorama ? Devenez membre

Fermer

Forum

HEMISPHERX BIO
3.900 USD
-0.89% 
valeur indicative 3.455 EUR

US42366C5094 HEB

AMEX données temps différé
  • ouverture

    3.750

  • clôture veille

    3.935

  • + haut

    3.940

  • + bas

    3.630

  • volume

    0

  • valorisation

    9 MUSD

  • capital échangé

    0.00%

  • dernier échange

    20.06.19 / 18:49:55

  • limite à la baisse

    Qu'est-ce qu'une limite à la hausse/baisse ?

    Fermer

    0.060

  • limite à la hausse

    Qu'est-ce qu'une limite à la hausse/baisse ?

    Fermer

    0.410

  • rendement estimé 2019

    -

  • PER estimé 2019

    Qu'est-ce que le PER ?

    Fermer

    -

  • dernier dividende

    -

  • date dernier dividende

    -

  • Éligibilité

    -

  • + Alerte

  • + Portefeuille

  • + Liste

Retour au sujet HEMISPHERX BIOPHARMA INC

HEMISPHERX BIO : Hunger strike ends with promise to addr

nilufage
11 févr. 201318:27

Hunger strike ends with promise to address chronic lack of fatigue drugs
Robert Miller, a chronic fatigue syndrome patient and advocate for finding effective treatments for the disorder, has ended his hunger strike after 11 days.

Courtney Miller, his wife, said he ended the strike Friday following a commitment from the Assistant Secretary of Health’s office to engage in a Food and Drug Administration scientific and stakeholders meeting this spring to advance treatments for CFS.

“He is recuperating well,” she said.

Miller began the hunger strike a few days before the FDA was scheduled to rule on Hemispherx BioPharma’s (NYSE Amex:HEB) new drug application for Ampligen, an experimental treatment for CFS that the Philadelphia biotechnology company has had under development for more than three decades.

You can read my interview with Miller during the early days of his hunger strike here.

The FDA earlier this month followed the advice of its advisory committee and did not approve the application, and told Hemispherx its needs to conduct additional testing to demonstrate the drug’s safety and effectiveness.

Estimates by health officials state the condition afflicts more than 1 million Americans.

During his 11-day hunger strike, Miller, who lives in Reno, Nev., had the support of U.S. Sen. Harry Reid, D-Nev., who discussed the need to find a treatment for chronic fatigue syndrome with officials at the Department of Health and Human Services.

Courtney Miller said thousands of letters, emails and phone calls were made to federal health agencies and congressional representatives in the past 11 days, which, she said, “demonstrated to our government how widespread and serious chronic fatigue syndrome is.”

In a statement, Robert Miller said: “Thank you to Senator Reid for being a continued voice at the highest levels of government, especially this week, for me and a million Americans who are seriously ill with CFS and have no treatments at all. I am eager to work with the right people in our federal health agencies to bring strong science to bear on research and treatments for CFS.”

Signaler un abus

Vous devez être membre pour ajouter un commentaire.
Vous êtes déjà membre ? Connectez-vous
Pas encore membre ? Devenez membre gratuitement

2 réponses

  • sud30000
    11 février 201319:51

    merci pour ton travail l'amie, crois tu que l'on y arivera un jour ?

    Signaler un abus

  • ldemol
    12 février 201309:23

    Je commence aussi demain !!

    Signaler un abus

Retour au sujet HEMISPHERX BIOPHARMA INC

Signaler le message

Fermer

Qui a recommandé ce message ?

Fermer

Mes listes

Une erreur est survenue pendant le chargement de la liste

valeur

dernier

var.

Les Risques en Bourse

Fermer